NCT05431270
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with prior T-cell, NK cell, or CD73 inhibitor therapy; Prior checkpoint inhibitor anti PD-1 & anti PD-L1 therapies are allowed (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab)
https://ClinicalTrials.gov/show/NCT05431270